Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda Playbook

Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.

The Bottom Fishing Club: Morningstar's Valuation + Future Growth = Turnaround Play

Discover why Morningstar is a top value pick in financial data stocks with strong EPS growth, low valuation, and a bullish ...